patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1 value | histology stringclasses 3 values | stage_at_diagnosis stringclasses 3 values | driver_mutation stringclasses 7 values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2 values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6 values | overall_survival_months float64 4 83 | censored bool 2 classes | msi_status stringclasses 2 values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1 value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_701741 | REC_0000501 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 3.6 | 64 | female | 0 | 62 | 6 | 7 | pembrolizumab 200 mg q3w | 15 | false | MSS | 2026-03-15T05:35:56.957787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115168 | REC_0000502 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 8.2 | 61 | male | 0 | 25 | 5.9 | 6 | alectinib 600 mg BID | 12 | true | MSS | 2026-03-15T05:35:56.958025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457889 | REC_0000503 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 8.1 | 66 | female | 0 | 42 | 3.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.3 | true | MSS | 2026-03-15T05:35:56.958261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160209 | REC_0000504 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.2 | 56 | female | 1 | 6 | 4.7 | 6 | alectinib 600 mg BID | 11.7 | false | MSI-H | 2026-03-15T05:35:56.958499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798095 | REC_0000505 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 4.2 | 73 | male | 2 | 19 | 2.8 | 5 | pembrolizumab 200 mg q3w | 5.8 | false | MSS | 2026-03-15T05:35:56.958802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334395 | REC_0000506 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 11.3 | 84 | female | 1 | 19 | 4.2 | 0 | osimertinib 80 mg daily | 34.3 | false | MSI-H | 2026-03-15T05:35:56.959055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258386 | REC_0000507 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 14.2 | 72 | female | 0 | 21 | 5.2 | 5 | entrectinib 600 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:35:56.959310+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538417 | REC_0000508 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 5.4 | 77 | female | 2 | 15 | 4.1 | 2 | entrectinib 600 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:56.959737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767066 | REC_0000509 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 15 | 4.7 | 71 | female | 1 | 22 | 3.7 | 8 | osimertinib 80 mg daily | 8.7 | false | MSS | 2026-03-15T05:35:56.959992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785761 | REC_0000510 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 12.2 | 71 | female | 0 | 16 | 4.1 | 5 | entrectinib 600 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:56.960310+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382700 | REC_0000511 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.1 | 52 | male | 0 | 27 | 5.4 | 7 | osimertinib 80 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:56.960578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124911 | REC_0000512 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 11.9 | 80 | female | 2 | 13 | 5.1 | 2 | alectinib 600 mg BID | 26.2 | false | MSS | 2026-03-15T05:35:56.960845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521002 | REC_0000513 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 16.8 | 73 | female | 2 | 27 | 4.3 | 5 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:35:56.961098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340888 | REC_0000514 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 2.6 | 67 | male | 1 | 76 | 3.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 9 | false | MSS | 2026-03-15T05:35:56.961334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764756 | REC_0000515 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 3.9 | 52 | female | 0 | 8 | 5.9 | 2 | pembrolizumab 200 mg q3w | 19.2 | false | MSS | 2026-03-15T05:35:56.961569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183091 | REC_0000516 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 8.1 | 75 | female | 2 | 14 | 6.9 | 3 | pembrolizumab 200 mg q3w | 8.9 | true | MSS | 2026-03-15T05:35:56.961805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_348794 | REC_0000517 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 12.7 | 73 | female | 2 | 22 | 5.3 | 2 | sotorasib 960 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:56.962046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545731 | REC_0000518 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 6.7 | 85 | female | 1 | 11 | 5.7 | 8 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:56.962277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783970 | REC_0000519 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 17 | 5.3 | 79 | female | 2 | 20 | 6.7 | 4 | pembrolizumab 200 mg q3w | 12.5 | true | MSS | 2026-03-15T05:35:56.962512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696956 | REC_0000520 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 14.9 | 64 | male | 1 | 14 | 4.4 | 1 | alectinib 600 mg BID | 20.2 | false | MSI-H | 2026-03-15T05:35:56.962751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753701 | REC_0000521 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 9.7 | 76 | female | 1 | 6 | 5.4 | 6 | pembrolizumab 200 mg q3w | 7 | false | MSS | 2026-03-15T05:35:56.963084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425124 | REC_0000522 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8 | 59 | male | 0 | 72 | 4.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.2 | true | MSS | 2026-03-15T05:35:56.963323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649752 | REC_0000523 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 13.8 | 63 | male | 1 | 7 | 6.5 | 6 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:56.963572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608199 | REC_0000524 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 13.6 | 51 | female | 0 | 17 | 6.2 | 2 | entrectinib 600 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:56.963807+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752396 | REC_0000525 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6 | 71 | female | 1 | 75 | 6.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.3 | true | MSS | 2026-03-15T05:35:56.964037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755928 | REC_0000526 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 13.3 | 79 | male | 1 | 10 | 7 | 5 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:56.964337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784691 | REC_0000527 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 16.1 | 65 | female | 1 | 13 | 7.2 | 4 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:56.964580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993415 | REC_0000528 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 23.7 | 74 | female | 1 | 10 | 5.1 | 4 | entrectinib 600 mg daily | 7.9 | false | MSI-H | 2026-03-15T05:35:56.964822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321908 | REC_0000529 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 9.5 | 66 | male | 1 | 11 | 7.2 | 3 | pembrolizumab 200 mg q3w | 7.5 | false | MSS | 2026-03-15T05:35:56.965076+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599797 | REC_0000530 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 3.1 | 68 | female | 0 | 10 | 5.9 | 4 | osimertinib 80 mg daily | 14.9 | false | MSS | 2026-03-15T05:35:56.965326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323072 | REC_0000531 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12 | 63 | male | 1 | 16 | 6.5 | 6 | sotorasib 960 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:56.965566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699012 | REC_0000532 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 5.4 | 52 | male | 0 | 36 | 5.2 | 1 | pembrolizumab 200 mg q3w | 23.8 | true | MSS | 2026-03-15T05:35:56.965797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690978 | REC_0000533 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.1 | 83 | female | 3 | 11 | 4.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 17.4 | true | MSS | 2026-03-15T05:35:56.966027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340999 | REC_0000534 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 4.7 | 54 | female | 0 | 13 | 4.4 | 1 | entrectinib 600 mg daily | 25.9 | false | MSS | 2026-03-15T05:35:56.966370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665351 | REC_0000535 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 4.5 | 52 | male | 0 | 33 | 6.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.6 | false | MSS | 2026-03-15T05:35:56.966635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397180 | REC_0000536 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.4 | 73 | female | 1 | 21 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 15.3 | true | MSS | 2026-03-15T05:35:56.966881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418053 | REC_0000537 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 8.9 | 77 | female | 1 | 5 | 6.3 | 0 | osimertinib 80 mg daily | 32.9 | false | MSS | 2026-03-15T05:35:56.967121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291808 | REC_0000538 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 34 | 18.3 | 70 | female | 2 | 12 | 5.8 | 1 | sotorasib 960 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:56.967380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340192 | REC_0000539 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 22 | 9.1 | 56 | male | 0 | 17 | 6.5 | 0 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:56.967637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_821276 | REC_0000540 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.7 | 55 | male | 0 | 51 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:56.967989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228037 | REC_0000541 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.9 | 72 | female | 0 | 40 | 4.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.9 | false | MSS | 2026-03-15T05:35:56.968347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354649 | REC_0000542 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 5 | 61 | female | 0 | 15 | 5.5 | 5 | alectinib 600 mg BID | 7.4 | false | MSS | 2026-03-15T05:35:56.968647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725307 | REC_0000543 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.3 | 67 | female | 0 | 46 | 7.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.9 | false | MSS | 2026-03-15T05:35:56.968901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155256 | REC_0000544 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 11.2 | 60 | male | 1 | 24 | 6.2 | 4 | entrectinib 600 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:56.969199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672887 | REC_0000545 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 11.3 | 71 | female | 1 | 22 | 5.8 | 1 | sotorasib 960 mg daily | 23.8 | false | MSI-H | 2026-03-15T05:35:56.969441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160035 | REC_0000546 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 8.3 | 66 | female | 0 | 22 | 4.9 | 5 | sotorasib 960 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:56.969673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887447 | REC_0000547 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 12.6 | 63 | female | 1 | 11 | 7.6 | 2 | sotorasib 960 mg daily | 15.8 | true | MSS | 2026-03-15T05:35:56.970035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787773 | REC_0000548 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.3 | 67 | male | 0 | 30 | 7.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.1 | false | MSS | 2026-03-15T05:35:56.970284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233786 | REC_0000549 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 17.6 | 55 | female | 1 | 13 | 4.2 | 2 | entrectinib 600 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:35:56.970527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412220 | REC_0000550 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.2 | 71 | female | 1 | 8 | 3.2 | 2 | alectinib 600 mg BID | 13.4 | true | MSI-H | 2026-03-15T05:35:56.970768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634353 | REC_0000551 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 9.2 | 71 | female | 2 | 5 | 6.8 | 1 | entrectinib 600 mg daily | 21.1 | true | MSS | 2026-03-15T05:35:56.971016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256926 | REC_0000552 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 27 | 7.5 | 70 | female | 2 | 8 | 5.3 | 0 | entrectinib 600 mg daily | 31.2 | false | MSS | 2026-03-15T05:35:56.971250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465918 | REC_0000553 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.9 | 86 | female | 2 | 23 | 6.6 | 5 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:56.971483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144821 | REC_0000554 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 15.9 | 68 | female | 0 | 13 | 4.9 | 2 | sotorasib 960 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:56.971715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448727 | REC_0000555 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.4 | 68 | female | 1 | 66 | 4.7 | 9 | carboplatin + paclitaxel + pembrolizumab | 7.5 | true | MSS | 2026-03-15T05:35:56.971950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106590 | REC_0000556 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 9.8 | 62 | male | 1 | 10 | 5 | 7 | sotorasib 960 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:56.972242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314012 | REC_0000557 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 12.1 | 67 | female | 1 | 21 | 6.2 | 2 | entrectinib 600 mg daily | 6.6 | false | MSS | 2026-03-15T05:35:56.972553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332515 | REC_0000558 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 10.8 | 70 | female | 0 | 9 | 4.4 | 5 | entrectinib 600 mg daily | 16.6 | true | MSI-H | 2026-03-15T05:35:56.972870+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485780 | REC_0000559 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 10.8 | 80 | female | 1 | 12 | 2.9 | 5 | sotorasib 960 mg daily | 12 | false | MSS | 2026-03-15T05:35:56.973150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600497 | REC_0000560 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 19 | 82 | female | 0 | 15 | 6.2 | 5 | sotorasib 960 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:35:56.973486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849031 | REC_0000561 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.3 | 63 | female | 0 | 27 | 6.2 | 7 | alectinib 600 mg BID | 13.3 | true | MSS | 2026-03-15T05:35:56.973731+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326549 | REC_0000562 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 9.6 | 84 | female | 1 | 8 | 5.5 | 7 | sotorasib 960 mg daily | 10.2 | true | MSS | 2026-03-15T05:35:56.974000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952454 | REC_0000563 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 12 | 5.2 | 58 | male | 1 | 48 | 4.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 6 | true | MSS | 2026-03-15T05:35:56.974272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255350 | REC_0000564 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 16.6 | 58 | male | 1 | 19 | 5.2 | 4 | alectinib 600 mg BID | 14.5 | true | MSS | 2026-03-15T05:35:56.974511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576164 | REC_0000565 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11 | 63 | female | 0 | 15 | 5 | 6 | osimertinib 80 mg daily | 20.2 | true | MSI-H | 2026-03-15T05:35:56.974748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937941 | REC_0000566 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 13.1 | 58 | male | 1 | 19 | 4.9 | 3 | alectinib 600 mg BID | 10.9 | true | MSI-H | 2026-03-15T05:35:56.974981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845801 | REC_0000567 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.2 | 53 | male | 0 | 12 | 7.9 | 6 | osimertinib 80 mg daily | 12.7 | true | MSS | 2026-03-15T05:35:56.975217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167926 | REC_0000568 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 3.3 | 62 | female | 1 | 46 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.9 | false | MSS | 2026-03-15T05:35:56.975450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_240979 | REC_0000569 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 15 | 11.3 | 71 | female | 1 | 19 | 4.8 | 0 | entrectinib 600 mg daily | 28.9 | true | MSS | 2026-03-15T05:35:56.975683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_447103 | REC_0000570 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 9.3 | 59 | female | 1 | 6 | 6.8 | 2 | osimertinib 80 mg daily | 20.6 | true | MSS | 2026-03-15T05:35:56.975915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144944 | REC_0000571 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 8.8 | 63 | male | 0 | 14 | 5.6 | 1 | sotorasib 960 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:56.976191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408574 | REC_0000572 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 13.1 | 67 | female | 0 | 24 | 4.1 | 4 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:35:56.976428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473201 | REC_0000573 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 14 | 13.6 | 71 | female | 1 | 14 | 7.6 | 1 | entrectinib 600 mg daily | 21.3 | false | MSS | 2026-03-15T05:35:56.976740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790567 | REC_0000574 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 8 | 63 | male | 1 | 21 | 5.9 | 2 | osimertinib 80 mg daily | 23.1 | true | MSS | 2026-03-15T05:35:56.976976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262284 | REC_0000575 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 18.4 | 83 | female | 3 | 20 | 5 | 1 | osimertinib 80 mg daily | 15.5 | true | MSS | 2026-03-15T05:35:56.977213+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407879 | REC_0000576 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 13.7 | 59 | female | 1 | 24 | 6.4 | 2 | alectinib 600 mg BID | 19.5 | false | MSS | 2026-03-15T05:35:56.977447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259771 | REC_0000577 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 10.7 | 68 | female | 0 | 21 | 8.2 | 2 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:56.977680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846433 | REC_0000578 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.4 | 70 | male | 1 | 17 | 4.7 | 5 | osimertinib 80 mg daily | 18.4 | true | MSI-H | 2026-03-15T05:35:56.977916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908195 | REC_0000579 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.9 | 59 | female | 1 | 11 | 5.1 | 7 | osimertinib 80 mg daily | 10.1 | true | MSI-H | 2026-03-15T05:35:56.978152+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327786 | REC_0000580 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 2.2 | 66 | female | 1 | 29 | 6.4 | 4 | pembrolizumab 200 mg q3w | 14.1 | true | MSS | 2026-03-15T05:35:56.978379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634367 | REC_0000581 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 12.9 | 67 | male | 1 | 18 | 5 | 7 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:56.978620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236204 | REC_0000582 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.3 | 76 | female | 2 | 15 | 3.3 | 4 | sotorasib 960 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:35:56.978865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802844 | REC_0000583 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 4 | 62 | male | 0 | 47 | 6.6 | 8 | carboplatin + paclitaxel + pembrolizumab | 19.1 | true | MSS | 2026-03-15T05:35:56.979113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235280 | REC_0000584 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.7 | 75 | male | 1 | 33 | 4.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 15.2 | true | MSS | 2026-03-15T05:35:56.979358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690851 | REC_0000585 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 7.1 | 65 | male | 1 | 15 | 4.5 | 1 | entrectinib 600 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:56.979605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472431 | REC_0000586 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 5.4 | 69 | female | 0 | 15 | 4.1 | 3 | alectinib 600 mg BID | 4.5 | false | MSS | 2026-03-15T05:35:56.979939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560658 | REC_0000587 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 4.8 | 70 | female | 1 | 14 | 7.1 | 5 | pembrolizumab 200 mg q3w | 11.5 | true | MSS | 2026-03-15T05:35:56.980299+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410081 | REC_0000588 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 8.6 | 70 | female | 3 | 19 | 4 | 6 | entrectinib 600 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:56.980557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774287 | REC_0000589 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 5 | 76 | female | 2 | 26 | 5.5 | 7 | pembrolizumab 200 mg q3w | 12.3 | false | MSS | 2026-03-15T05:35:56.980791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483506 | REC_0000590 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 8 | 73 | female | 3 | 20 | 3.6 | 7 | pembrolizumab 200 mg q3w | 6 | true | MSS | 2026-03-15T05:35:56.981048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413100 | REC_0000591 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 15.7 | 76 | female | 2 | 20 | 5.8 | 2 | sotorasib 960 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:35:56.981319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167433 | REC_0000592 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 15.4 | 86 | female | 2 | 23 | 3.2 | 4 | osimertinib 80 mg daily | 14.5 | true | MSI-H | 2026-03-15T05:35:56.981589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241540 | REC_0000593 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 8.6 | 69 | male | 1 | 7 | 6.3 | 0 | osimertinib 80 mg daily | 51.3 | false | MSS | 2026-03-15T05:35:56.981827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998077 | REC_0000594 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.2 | 63 | female | 1 | 52 | 5.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.4 | true | MSS | 2026-03-15T05:35:56.982091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826412 | REC_0000595 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 5.8 | 75 | female | 2 | 73 | 6.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.4 | true | MSS | 2026-03-15T05:35:56.982322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808744 | REC_0000596 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 8.9 | 67 | male | 0 | 12 | 4.8 | 1 | alectinib 600 mg BID | 13.3 | false | MSS | 2026-03-15T05:35:56.982558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973107 | REC_0000597 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 10.4 | 72 | female | 1 | 12 | 5.1 | 1 | entrectinib 600 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:56.982802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143450 | REC_0000598 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 12 | 73 | female | 2 | 17 | 7.1 | 1 | pembrolizumab 200 mg q3w | 17.1 | true | MSI-H | 2026-03-15T05:35:56.983048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245986 | REC_0000599 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 17.8 | 63 | male | 0 | 12 | 8 | 5 | entrectinib 600 mg daily | 7.7 | false | MSS | 2026-03-15T05:35:56.983413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444726 | REC_0000600 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 14.3 | 66 | female | 1 | 9 | 6.2 | 1 | osimertinib 80 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:56.983658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.